Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00955799 · ClinicalTrials.gov registry record · Phase 3
Efficacy, Safety, Tolerability of Neramexane in Patients With Subjective Tinnitus
A Phase 3 study, sponsored by Merz Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 455
- Enrollment target
NCT00955799 is a Phase 3 study that has completed, run by Merz Pharmaceuticals. The registered enrollment target is 455 participants.
The verdict
NCT00955799, a Phase 3 study, has completed, sponsored by Merz Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 455 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the safety and efficacy of neramexane mesylate in the treatment of subjective tinnitus in comparison to placebo.
Interventions
- DRUG Placebo
- DRUG Neramexane mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 455 participants |
| Start Date | 2009-09 |
| Est. Completion | 2011-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00955799
The ClinicalTrials.gov registry entry for NCT00955799 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 455 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merz Pharmaceuticals, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00955799 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00955799 about?
NCT00955799 is a clinical study titled "Efficacy, Safety, Tolerability of Neramexane in Patients With Subjective Tinnitus". The purpose of this study is to investigate the safety and efficacy of neramexane mesylate in the treatment of subjective tinnitus in comparison to placebo.
What is the current status of trial NCT00955799?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 455 participants. The study started on 2009-09. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00955799?
The interventions under investigation include: Placebo (DRUG), Neramexane mesylate (DRUG).
Who is sponsoring clinical trial NCT00955799?
This trial is sponsored by Merz Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.